Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Recruiting
Observational Study
Cardiac Amyloidosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 25 (estimated)
- Sponsor
- University Hospital, Essen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age \> 40 years
* proven Amyloidosis (ATTR or AL)
* Women: negative pregnancy test less than weeks prior imaging.
Exclusion Criteria:
* Patients receiving amyloidosis-specific treatment prior study inclusion.
* Patients participating in other clinical trails for treatment of…
Contacts